Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

1096 ARTÍCULOS , VIENDO DEL 886 AL 900

Steroid-Responsive Progressive Subacute Cerebellar Ataxia: An Unrecognized Subtype of Immune-Mediated Ataxia

Choi EH, Park JH, Choi JY, Kim JS.

Cerebellum. 2025 Apr 5;24(3):80. doi: 10.1007/s12311-025-01829-8.

Etiologies of Acute Ataxia in Children: A Systematic Review of 1167 Subjects

Jones C, Amendum P, DelVecchio M, Aronoff S.

J Child Neurol. 2025 Dec 1:8830738251396192. doi: 10.1177/08830738251396192. Online ahead of print.

Clinical and molecular assessment of a spastic ataxia 4 (SPAX4) patient with a novel variant in the MTPAP gene, and a systematic review

Ravanbod M, Mohammadi M, Soleimani P, Zemorshidi F, Nafissi S, Alavi A.

Gene. 2025 Jul 10;956:149463. doi: 10.1016/j.gene.2025.149463. Epub 2025 Mar 31.

Clinical Reasoning: A Toddler With Acute-Onset Hypotonia, Areflexia, and Ataxia

Pence KL, Clark RA.

Neurology. 2025 May 13;104(9):e213593. doi: 10.1212/WNL.0000000000213593. Epub 2025 Apr 14.

Home-Based Rehabilitation With Frenkel's Exercises for Adrenomyeloneuropathy: A Case Report

Ishikawa T.

Cureus. 2025 Mar 20;17(3):e80878. doi: 10.7759/cureus.80878. eCollection 2025 Mar.

Translational Relevance of SCA1 Models for the Development of Therapies for Spinocerebellar Ataxia Type 1

Plotnikova E, Ageeva T, Sufianov A, Sufianova G, Rizvanov A, Mukhamedshina Y.

Biomedicines. 2025 Dec 12;13(12):3066. doi: 10.3390/biomedicines13123066.

Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance

Lin X, Qiu Y, Soni A, Stuschke M, Iliakis G.

Mol Ther Oncol. 2025 Jan 14;33(1):200934. doi: 10.1016/j.omton.2025.200934. eCollection 2025 Mar 20.

Cerebellar abiotrophy in a quarter horse foal

Primo ALM, Assis DM, Santos VGS, de Melo LRB, da Nóbrega LD, Medeiros Dantas AF, Maciel TA.

J Equine Vet Sci. 2025 Apr;147:105386. doi: 10.1016/j.jevs.2025.105386. Epub 2025 Feb 16.

Sez6l2-associated cerebellar ataxia: case report and review of the literature

Chang C, Yang X, Xu G, Yan Y, Wang S.

Neurol Sci. 2025 Aug;46(8):4047-4049. doi: 10.1007/s10072-025-08047-4. Epub 2025 Feb 20.

Cerebellar Ataxia-deafness-narcolepsy (ADCA) syndrome. Description of a variable family phenotype

Abenza-Abildúa MJ, Palmí-Cortés I, Ojeda-Ruiz de Luna J, Gómez-Aceña Á, Olmedo-Menchén T, Lanz-Santos E.

Acta Neurol Belg. 2025 Oct;125(5):1395-1399. doi: 10.1007/s13760-025-02776-1. Epub 2025 Apr 26.

Purkinje cell development and degeneration in the spastic Han-Wistar rat model of ataxia

Bellafard H, Pelayo T, Aghopoo M, Sarhangnejad D, Gaft S, Zuccherato LW, Amorim CEG, Bellard ME.

Res Sq [Preprint]. 2025 Oct 27:rs.3.rs-7706512. doi: 10.21203/rs.3.rs-7706512/v1.

Purkinje cell development and degeneration in the spastic Han-Wistar rat model of ataxia

Bellafard H, Pelayo T, Aghopoo M, Sarhangnejad D, Gaft S, Zuccherato LW, Amorim CEG, de Bellard ME.

bioRxiv [Preprint]. 2025 Sep 23:2025.09.23.677887. doi: 10.1101/2025.09.23.677887.

Early onset development of hypertrophic cardiomyopathy in less than 1 year in a patient with familial Friedrich's ataxia: Case report

Ouaddouh Y, Bouyaddid S, Bazid Z, Ismaili N, El Ouafi N.

Radiol Case Rep. 2025 Mar 28;20(6):3016-3020. doi: 10.1016/j.radcr.2025.03.001. eCollection 2025 Jun.

Viral vector-mediated SLC9A6 gene replacement reduces cerebellar dysfunction in the shaker rat model of Christianson syndrome

Anderson CJ, Figueroa KP, Paul S, Gandelman M, Dansithong W, Katakowski JA, Scoles DR, Pulst SM.

bioRxiv [Preprint]. 2025 Jan 16:2024.10.31.621435. doi: 10.1101/2024.10.31.621435.

Omaveloxolone (Skyclarys): Therapeutic area: Friedreich’s ataxia: Reimbursement Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Nov. Report No.: SR0864-Clinical_Review.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias